Developing Drugs for Core Social and Communication Impairment in Autism

Child and Adolescent Psychiatric Clinics of North America

Volumn 17, Issue 4, 2008, Pages 787-801

  Posey, David J ^a   Erickson, Craig A ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CITALOPRAM; CYCLOSERINE; DEXTROMETHORPHAN; DONEPEZIL; ESCITALOPRAM; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; LAMOTRIGINE; MEMANTINE; NALTREXONE; OLANZAPINE; OXYTOCIN; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SECRETIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; ZIPRASIDONE;

ADULT; AGGRESSION; AGITATION; AUTISM; CHILD; CLINICAL TRIAL; COMMUNICATION DISORDER; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; ECHOLALIA; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIALIZATION; STEREOTYPY; SYMPTOM; TIC; WEIGHT GAIN;

ADOLESCENT; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMMUNICATION DISORDERS; HUMANS; PSYCHOTROPIC DRUGS; RESEARCH; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 50449092541     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2008.06.010     Document Type: Review

References (69)

1. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 36 8 (2006) 1101-1114
2. Aman M.G., Lam K.S., and Van Bourgondien M.E. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 15 1 (2005) 116-126
3. Bailey A., Le Couteur A., Gottesman I., et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 25 1 (1995) 63-77
4. Redcay E., and Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biol Psychiatry 58 1 (2005) 1-9
5. Schultz R.T., Chawarska K., and Volkmar F. The social brain in autism: perspectives from neuropsychology and neuroimaging. In: Moldin S.O., and Rubenstein J.L.R. (Eds). Understanding autism: from basic neuroscience to treatment (2006), CRC Press, Boca Raton (FL) 323-348
6. Lord C., Rutter M., and Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24 5 (1994) 659-685
7. Chakrabarti S., and Fombonne E. Pervasive developmental disorders in preschool children. JAMA 285 24 (2001) 3093-3099
8. McDougle C.J., Scahill L., McCracken J.T., et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9 1 (2000) 201-224
9. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 9 (1997) 581-588
10. Geller E., Ritvo E.R., Freeman B.J., et al. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 307 3 (1982) 165-169
11. Ritvo E.R., Freeman B.J., Yuwiler A., et al. Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull 22 1 (1986) 133-140
12. Campbell M., Adams P., Small A.M., et al. Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 27 4 (1988) 434-439
13. Sahley T.L., and Panksepp J. Brain opioids and autism: an updated analysis of possible linkages. J Aut Dev Disorders 17 2 (1987) 201-216
14. Campbell M., Anderson L.T., Small A.M., et al. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 32 6 (1993) 1283-1291
15. Willemsen-Swinkels S.H., Buitelaar J.K., Weijnen F.G., et al. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 58 3 (1995) 203-215
16. Willemsen-Swinkels S.H., Buitelaar J.K., Nijhof G.J., et al. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry 52 9 (1995) 766-773
17. Guy W. ECDEU assessment manual for psychopharmacology. Publication No. 76-338 (1976), U.S. DHEW, NIMH, Washington, DC
18. Horvath K., Stefanatos G., Sokolski K.N., et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 9 1 (1998) 9-15
19. McDougle C.J., Naylor S.T., Cohen D.J., et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53 11 (1996) 1001-1008
20. McDougle C.J., Kresch L.E., and Posey D.J. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30 5 (2000) 427-435
21. Hollander E., Phillips A., Chaplin W., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30 3 (2005) 582-589
22. Scahill L., Riddle M., McSwiggin-Hardin M., et al. Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. Journal of American Academy of Child and Adolescent Psychiatry 36 (1997) 844-852
23. Posey D.J., Erickson C.A., Stigler K.A., et al. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 16 1-2 (2006) 181-186
24. DeLong G.R., Ritch C.R., and Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 44 10 (2002) 652-659
25. McDougle C.J., Holmes J.P., Carlson D.C., et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55 7 (1998) 633-641
26. Research Units on Pediatric Psychopharmaology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347 5 (2002) 314-321
27. Aman M.G., Singh N.N., Stewart A.W., et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 5 (1985) 485-491
28. McDougle C.J., Scahill L., Aman M.G., et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162 6 (2005) 1142-1148
29. Freeman B.J., Ritvo E.R., Yokota A., et al. A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Psychiatry 25 1 (1986) 130-136
30. Scahill L., McDougle C.J., Williams S.K., et al. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 45 9 (2006) 1114-1123
31. Shea S., Turgay A., Carroll A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 5 (2004) e634-e641
32. Posey D.J., Walsh K.H., Wilson G.A., et al. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 9 4 (1999) 273-276
33. Nagaraj R., Singhi P., and Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 21 6 (2006) 450-455
34. Schopler E., Reichler R.J., DeVellis R.F., et al. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 10 1 (1980) 91-103
35. Luby J., Mrakotsky C., Stalets M.M., et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 16 5 (2006) 575-587
36. Potenza M.N., Holmes J.P., Kanes S.J., et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19 1 (1999) 37-44
37. Malone R.P., Cater J., Sheikh R.M., et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40 8 (2001) 887-894
38. Kemner C., Willemsen-Swinkels S.H., de Jonge M., et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22 5 (2002) 455-460
39. Hollander E., Wasserman S., Swanson E.N., et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16 5 (2006) 541-548
40. ClinicalTrials.gov. Available at:. http://www.clinicaltrials.gov Accessed May 16, 2008
41. Niederhofer H. Treating autism pharmacologically: also tacrine might improve symptomatology in some cases. J Child Neurol 22 8 (2007) 1054
42. Hardan A.Y., and Handen B.L. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 12 3 (2002) 237-241
43. Doyle R.L., Frazier J., Spencer T.J., et al. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord 9 3 (2006) 543-549
44. Chez M.G., Buchanan T.M., Becker M., et al. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol 1 2 (2003) 83-88
45. Chez M.G., Aimonovitch M., Buchanan T., et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 19 3 (2004) 165-169
46. Nicolson R., Craven-Thuss B., and Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol 16 5 (2006) 621-629
47. Fish B. Children's Psychiatric Rating Scale. Psychopharmacol Bull 21 (1985) 753-770
48. Carlsson M.L. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. J Neural Transm 105 4-5 (1998) 525-535
49. Erickson CA, McDougle CJ, Stigler KA, et al. Glutamatergic function in autism. In: Heresco-Levy U, editor. Glutamate in neuropsychiatric disorders. Trivandrum, Kerala (India): Research Signpost, in press.
50. Coyle J.T., Leski M.L., and Morrison J.H. The diverse role of L-glutamic acid in brain signal transduction. In: Davis K.L., Charney D., Coyle J.T., et al. (Eds). Neuropsychopharmacology: the fifth generation of progress (2002), Lippincott Williams & Williams, Philadelphia 71-90
51. Uvebrant P., and Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 25 6 (1994) 284-289
52. Davanzo P.A., and King B.H. Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation. J Child Adolesc Psychopharmacol 6 4 (1996) 273-279
53. Belsito K.M., Law P.A., Kirk K.S., et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31 2 (2001) 175-181
54. Krug D.A., Arick J., and Almond P. Autism behavior checklist record form (1993), PRO-ED, Austin (TX)
55. Lord C., Rutter M., Goode S., et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord 19 2 (1989) 185-212
56. Goff D.C., Tsai G., Levitt J., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56 1 (1999) 21-27
57. Heresco-Levy U., Ermilov M., Shimoni J., et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159 3 (2002) 480-482
58. Buchanan R.W., Javitt D.C., Marder S.R., et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164 10 (2007) 1593-1602
59. Posey D.J., Kem D.L., Swiezy N.B., et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 161 11 (2004) 2115-2117
60. King B.H., Wright D.M., Snape M., et al. Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. J Am Acad Child Adolesc Psychiatry 40 6 (2001) 654-657
61. King B.H., Wright D.M., Handen B.L., et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 40 6 (2001) 658-665
62. Erickson C.A., and Chambers J.E. Memantine for disruptive behavior in autistic disorder. J Clin Psychiatry 67 6 (2006) 1000
63. Erickson C.A., Posey D.J., Stigler K.A., et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 191 1 (2007) 141-147
64. Chez M.G., Burton Q., Dowling T., et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 22 5 (2007) 574-579
65. Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clin Psychopharmacol 27 3 (2007) 317-318
66. Owley T., Salt J., Guter S., et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 16 5 (2006) 517-524
67. Woodard C., Groden J., Goodwin M., et al. A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. Autism 11 1 (2007) 29-41
68. Bartz J.A., and Hollander E. The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior. Horm Behav 50 4 (2006) 518-528
69. Hollander E., Bartz J., Chaplin W., et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 61 4 (2007) 498-503